Effect of Botulinum Neurotoxin A Injection into the Submucoperichondrium of the Nasal Septum in Reducing Idiopathic Non-Allergic Rhinitis and Persistent Allergic Rhinitis

Iranian Journal of Otorhinolaryngology

Mehdi Abna¹  Keramat Mozafarinia¹  Narges khanjani² 

[1] Department of Otorhinolaryngology, Medical School, Kerman University of Medical Sciences and Health Services, Kerman, Iran.;Neurology Research Center, Shafa Hospital, Kerman University of Medical Sciences and Health Services, Kerman, Iran.;

关键词: Botulinum neurotoxin A;    Persistent allergic rhinitis;    Idiopathic rhinitis;    Submucoperichondrial injection;   

DOI  :  

来源: DOAJ

【 摘 要 】

Introduction: Submucoperichondrial injection of botulinum neurotoxin A (BTA) in the nasal septum is a promising therapeutic option in the treatment of persistent allergic rhinitis (AR) and non-allergic rhinitis, and is safer and more effective than intraturbinate injection in reducing clinical symptoms.   Materials and Methods: Forty patients diagnosed with persistent AR or non-allergic rhinitis referred to Shafa Medical Center affiliated to Kerman University of Medical Sciences were included in this study and were randomly allocated to the intervention or control groups. Patients received an injection of 80 units BTA (Dysport, Ipsen Ltd Company, UK) at a concentration of 200 mU/ml in normal saline on four spots in each side of the nose and were followed for 12 weeks. Data were analyzed using a chi-square or Fisher’s test, and Mann Whitney U test.   Results: The mean age of patients was 46.1±15.3 years, and the two groups did not differ significantly in demographic variables. The severity of rhinitis symptoms was reduced after 4 weeks of injections in the intervention group and then gradually decreased further until the 12th week. There was a statistically significant difference between the groups (P

【 授权许可】

Unknown